As of Wednesday afternoon, Natco Pharma's shares were trading at Rs 1,559.15, reflecting a 1.99% increase, while the BSE Sensex experienced a slight drop.

On Wednesday, shares rose by up to 2.61% to Rs 1,568.75 during intraday trading.

Headquartered in Hyderabad, India, Natco Pharma operates in the US, Canada, and Europe, focusing on pharmaceuticals.

Meanwhile, eGenesis is advancing its work in xenotransplantation, developing human-compatible organs to address global organ shortages through innovative genome engineering.

Natco Pharma's Canadian subsidiary recently announced an $8 million investment in biotechnology company eGenesis, aimed at developing compatible human organs for transplant.

This investment has positively influenced Natco's share price, which saw a notable increase following the announcement.

For the quarter ending June, Natco Pharma reported a consolidated profit after tax of Rs 668.5 crore, up from Rs 420.3 crore the previous year.

In fact, Natco Pharma's share price has surged nearly 20% over the past month and has risen 92% year-to-date.

The company's consolidated revenue for the same quarter was Rs 1,410.7 crore, compared to Rs 1,160.2 crore in the corresponding quarter last year.

Natco's EBITDA margin improved significantly to 60.5% in Q1 FY25, up from 47.2% in the previous year, with EBITDA reaching Rs 852.9 crore.

The stock reached an all-time high of Rs 1,598 per share, marking a 2.7% rise in intraday trade on Thursday.

Notably, eGenesis recently made headlines by performing the world's first porcine kidney transplant in a living patient, which was approved by the FDA.